JANX Live signals | Maximize Profits with Getagraph.com

SELL 4767 min ago

@ $47.42

Issued: 16 May 2024 @ 14:57

Return: -0.67%

Previous signal: May 15 - 13:13

Previous signal: Buy

Return: -1.70 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Stats
Today's Volume	557 601
Average Volume	1.15M
Market Cap	2.44B
EPS	$0 ( 2024-05-14 )
Next earnings date	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-39.25
ATR14	$1.180 (2.50%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Ra Capital Management, L.p.	Buy	1 397 849	Pre-Funded Warrants (Right to Buy)
2024-02-29	Avalon Ventures Xi, L.p.	Sell	447 949	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Sell	438 722	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Sell	84 985	Common Stock
2024-02-29	Avalon Ventures Xi, L.p.	Buy	31 456	Common Stock

INSIDER POWER
55.64
Last 96 transactions
Buy: 16 444 752 \| Sell: 7 280 818

Volume Correlation

Long: 0.45 (neutral)

Short: -0.53 (weak negative)

Signal:(55) Neutral

Janux Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Janux Therapeutics, Inc. Correlation - Currency/Commodity

0.11
( neutral )

0.42
( neutral )

0.00
( neutral )

0.46
( neutral )

0.55
( weak )

-0.38
( neutral )

Janux Therapeutics, Inc. Financials

Annual	2023
Revenue:	$8.08M
Gross Profit:	$6.13M (75.81 %)
EPS:	$-1.320

FY	2023
Revenue:	$8.08M
Gross Profit:	$6.13M (75.81 %)
EPS:	$-1.320

FY	2022
Revenue:	$8.61M
Gross Profit:	$7.77M (90.23 %)
EPS:	$-1.310

FY	2021
Revenue:	$3.64M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.794

Financial Reports:

No articles found.

Janux Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.